Pulmonology

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

Encouraging patients to reach out with questions may lead more to roll up their sleeves this season, Tochi Iroku-Malize, MD, told Patient Care.

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Hopkins, of the National Foundation for Infectious Diseases, is frustrated by the diminished societal response to the virus' circulation including ongoing low vaccination rates.

The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

Sanofi and SK bioscience expand collaboration on pneumococcal conjugate vaccines, including a 21-valent candidate for pediatric populations.

Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.

Your daily dose of the clinical news you may have missed.

The Prescription Drug User Fee Act date is set for May 7, 2025.

Your daily dose of the clinical news you may have missed.

A woman in her mid-50s arrives at the ED for suspected anaphylaxis; SOB has not responded to epinephrine and steroids. Does the CT scan suggest a Dx?

Your daily dose of the clinical news you may have missed.

Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.

Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.